Menu
Recruiting NCT07316101

Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery

No phase Interventional Pituitary Adenoma Craniopharyngioma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Anti-fog suction device-a 4 Fr multi-channel silicone catheter.
Who it may be relevant to
Registry conditions: Pituitary Adenoma, Craniopharyngioma. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this clinical trial is to learn if the anti-fog suction device works to keep the surgical view clear during endoscopic nose-to-pituitary operations and whether it lowers the chance of brain-fluid infection. It will also learn about the safety of the device. The main questions it aims to answer are: * Does the device reduce the total time the surgeon has to stop because the lens fogs up? * What medical problems (such as nose-bleed, tube blockage, or infection) do participants have when the device is used? Researchers will compare the anti-fog device to the usual "water-squirt" method to see if the device works better. Participants will: * Have either the device or the usual water method applied during their planned pituitary surgery * Stay in the hospital for the normal recovery period (about 3-5 days) and return for a routine check-up around day 7 * Allow the study team to record operating times, any fog-related pauses, and results of blood or spinal-fluid tests taken before and after surgery

Interventions

  • Device Anti-fog suction device-a 4 Fr multi-channel silicone catheter
    A single-use, sterile "anti-fog suction device" (a 4 Fr multi-channel silicone catheter) is introduced through the same nostril alongside the endoscope after induction of anaesthesia. The built-in micro-balloon is inflated with 1 ml air to anchor the tip in the posterior choana. Low-flow (2 L min-¹), filtered, room-temperature air is delivered through the central lumen, creating a gentle laminar stream that passes across the lens, continuously removing warm humid air and preventing condensatio

Primary outcome measures

  • Total duration of lens-fog interruptions (minutes) [Time frame: Before the Nasal Packing(2 hours roughly)]
Secondary outcome measures (2)
  • post-operative intracranial infection rate [Time frame: 7 days]
  • Total irrigation fluid volume used intra-operatively (ml) [Time frame: Before the nasal packing(2 hours roughly)]

Eligibility criteria

Inclusion criteria

  • Age 18-75 years
  • Pre-operative MRI/CT diagnosis of pituitary adenoma or craniopharyngioma ≤ \*3 cm without extensive skull-base invasion
  • Scheduled for elective endoscopic endonasal transsphenoidal resection
  • ASA physical status I-III
  • Able and willing to give written informed consent and comply with follow-up

Exclusion criteria

  • Severe nasal anatomical deformity, polyps, or prior nasal surgery preventing device placement
  • Active nasal or systemic infection (WBC > 10 × 10⁹/L, CRP ≥ 10 mg/L)
  • Known intracranial infection or ongoing CSF leak
  • Coagulopathy (PT > 14 s or APTT > 45 s) or anticoagulation that cannot be stopped ≥ 7 days
  • Allergy to silicone or medical-grade plastics
  • Planned combined transcranial or transorbital approach
  • Pregnancy or breastfeeding
  • Psychiatric or cognitive disorder precluding informed consent or follow-up

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Other

Study locations

China · 1 center
  • West China Hospital of Sichuan University — Chengdu

Identifiers

NCT: NCT07316101 · WestChinaH-HX-2025-06

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗